Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Topic
HER2
HER2-targeted therapy, oncology biosimilars, antibody-drug conjugates, coding, and access strategy.
Pipeline· May 27, 2026 · 7 min read
Antibody-drug conjugate access landscape: ADC coverage and pipeline watch
By Ran Chen#ADC#HER2#Prior Authorization